Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study

Authors Information
Article Notes and Dates
To Cite : Mansournia M A, Holakouie-Naieni K, Fahimfar N, Almasi-Hashiani A, Cheraghi Z, et al. Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2017 ;15(2):e42713. doi: 10.5812/ijem.42713.
Copyright: Copyright © 2017, International Journal of Endocrinology and Metabolism. .
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104(22): 2746-53[PubMed]
  • 2. Global status report on noncommunicable diseases. 2011;
  • 3. Keil U. The worldwide WHO MONICA Project: results and perspectives. 2005;
  • 4. Nichols M, Ownsend N, Luengo-Fernandez R, Leal J, Gray A. European cardiovascular disease statistics. Europ Society Cardiol. 2012;
  • 5. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009; 9: 167[DOI][PubMed]
  • 6. Talaei M, Sarrafzadegan N, Sarrafzadegan N, Sadeghi M, Oveisgharan S. Incidence of cardiovascular diseases in an Iranian population: the isfahan cohort study. Arch Iran Med. 2013; 16(3)
  • 7. Khalili D, Mosavi-Jarrahi A, Eskandari F, Mousavi-Jarrahi Y, Hadaegh F, Mohagheghi M, et al. Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran. PLoS One. 2012; 7(2): 31427[DOI][PubMed]
  • 8. Khalili D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PLoS One. 2014; 9(8): 105804[DOI][PubMed]
  • 9. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. East Mediterr Health J. 2009; 15(1): 157-66[PubMed]
  • 10. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962; 27(64): 58
  • 11. Keys A, Taylor H, Blackburn H. Coronary heart disease among Minnesota Business and Professional men followed fifteen years. Circulation . 1963; 28(381): 95
  • 12. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004; 90(6): 645-9[PubMed]
  • 13. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002; 359(9309): 881-4[DOI][PubMed]
  • 14. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003; 34(10): 2349-54[DOI][PubMed]
  • 15. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009; 10: 5[DOI][PubMed]
  • 16. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002; 47(6): 408-26[PubMed]
  • 17. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. American heart J. 2000; 139(3): 371-7
  • 18. Najafi-Ghezeljeh T, Ekman I, Nikravesh MY, Emami A. Adaptation and validation of the Iranian version of Angina Pectoris characteristics questionnaire. Int J Nurs Pract. 2008; 14(6): 470-6[DOI][PubMed]
  • 19. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract. 2007; 77(2): 251-7[DOI][PubMed]
  • 20. Khalili D, Hadaegh F, Fahimfar N, Shafiee G, Sheikholeslami F, Ghanbarian A, et al. Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart disease? 10-year follow-up in a Middle East population. J Epidemiol Community Health. 2012; 66(12): 1104-9[DOI][PubMed]
  • 21. Rose G. Variability of angina. Some implications for epidemiology. Br J Prev Soc Med. 1968; 22(1): 12-5[PubMed]
  • 22. Denes P, Larson JC, Lloyd-Jones DM, Prineas RJ, Greenland P. Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. JAMA. 2007; 297(9): 978-85[DOI][PubMed]
  • 23. Daviglus ML, Liao Y, Greenland P, Dyer AR, Liu K, Xie X, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA. 1999; 281(6): 530-6[PubMed]
  • 24. Hemingway H, Shipley M, Britton A, Page M, Macfarlane P, Marmot M. Prognosis of angina with and without a diagnosis: 11 year follow up in the Whitehall II prospective cohort study. BMJ. 2003; 327(7420): 895[DOI][PubMed]
  • 25. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2005; 149(4): 606-12[DOI][PubMed]
  • 26. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care. 2008; 31(11): 2154-9[DOI][PubMed]
  • 27. van der Heijden AA, Van't Riet E, Bot SD, Cannegieter SC, Stehouwer CD, Baan CA, et al. Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care. 2013; 36(11): 3498-502[DOI][PubMed]
  • 28. Cha SA, Yun JS, Lim TS, Min K, Song KH, Yoo KD, et al. Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes. PLoS One. 2016; 11(10): 164807[DOI][PubMed]
  • 29. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population. Cardiovasc Diabetol. 2010; 9: 84[DOI][PubMed]
  • 30. Wilson PW, D'Agostino RS, Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012; 125(7): 695-703 e1[DOI][PubMed]
  • 31. Bradley F, Cupples ME. Reducing the risk of recurrent coronary heart disease. We know a bit more about what doesn't work. BMJ. 1999; 318(7197): 1499-500[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check